GlaxoSmithKline wins an FDA nod for its GLP-1 diabetes drug albiglutide


After a three-month delay pushed pause on its commercial plans, GlaxoSmithKline ($GSK) has secured FDA approval for albiglutide, a new diabetes treatment that will contend for market share in a fast-crowding space.

The drug, which will be marketed as Tanzeum, is a once-weekly GLP-1 agonist that helps spur the body's natural insulin production in patients with Type 2 diabetes. Across its 5,000-patient clinical program, GSK found the drug could improve patients' hemoglobin A1c levels both when used as a monotherapy and in tandem with other diabetes drugs. On the safety side, Tanzeum will carry a black-box warning advising doctors that thyroid tumors have popped up in animal studies of drugs in the GLP-1 class.

GSK initially expected to win approval for Tanzeum in January, but the FDA requested more time to review its application, stalling the drugmaker's access to a GLP-1 market analysts figure could top out at $5 billion a year.

But few expect Tanzeum to take the lion's share of that total. Leading the market are Novo Nordisk's ($NVO) daily Victoza and AstraZeneca's ($AZN) weekly Bydureon, and coming down the pike is Eli Lilly's ($LLY) much-hyped dulaglutide, a once-a-week treatment that, unlike Tanzeum, proved noninferior to Novo's drug in a head-to-head trial.

And the market is only getting more crowded. Sanofi ($SNY) is planning an FDA submission for its GLP-1-targeting lixisenatide next year, and Boehringer Ingelheim recently rebooted its collaboration with Zealand Pharma by handing back a daily GLP-1 treatment in order to pick another candidate from a crop of compounds that includes some weekly formulations.

GSK's drug has already won approval in Europe, where it is marketed as Eperzan.

- here's the FDA's announcement

Related Articles:
With FDA decision looming, GlaxoSmithKline nails EU OK for diabetes drug albiglutide
GlaxoSmithKline's new diabetes drug faces delay at the FDA
GlaxoSmithKline reveals mixed results for diabetes contender in 'crowded area'